Beta Bionics (NASDAQ:BBNX) Shares Gap Down Following Analyst Downgrade

Beta Bionics, Inc. (NASDAQ:BBNX) shares gapped down prior to trading on Wednesday after Robert W. Baird lowered their price target on the stock from $28.00 to $14.00. The stock had previously closed at $13.97, but opened at $12.89. Robert W. Baird currently has a neutral rating on the stock. Beta Bionics shares last traded at $12.47, with a volume of 1,808,308 shares trading hands.

A number of other equities research analysts also recently weighed in on the company. Lake Street Capital lifted their target price on Beta Bionics from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Friday, January 9th. TD Cowen initiated coverage on shares of Beta Bionics in a research note on Monday, January 26th. They set a “hold” rating and a $17.00 target price on the stock. UBS Group raised shares of Beta Bionics to a “strong-buy” rating in a research note on Monday, February 9th. Stifel Nicolaus cut their price target on Beta Bionics from $25.00 to $22.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, Wall Street Zen downgraded Beta Bionics from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Beta Bionics has a consensus rating of “Moderate Buy” and a consensus price target of $23.33.

Insider Activity at Beta Bionics

In other Beta Bionics news, insider Mike Mensinger sold 2,200 shares of Beta Bionics stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $30.10, for a total value of $66,220.00. Following the transaction, the insider directly owned 80,752 shares of the company’s stock, valued at $2,430,635.20. The trade was a 2.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Stephen Feider sold 20,000 shares of the stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $29.53, for a total value of $590,600.00. Following the sale, the chief financial officer directly owned 42,614 shares of the company’s stock, valued at approximately $1,258,391.42. This trade represents a 31.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 32,490 shares of company stock valued at $960,835.

Beta Bionics News Roundup

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Q4 results showed accelerating revenue (Q4 net sales $32.1M, +57% y/y), expanding gross margin (59.0%) and a much larger installed base — evidence of product demand and scale. GlobeNewswire: Q4 & FY2025 Results
• Positive Sentiment: Management set 2026 revenue guidance of ~$130M–$135M and expects higher PBP reimbursement mix — a clear growth glidepath that supports medium‑term sales visibility. Seeking Alpha: 2026 Guidance
• Neutral Sentiment: Full Q4 earnings materials and multiple call/transcript sources are available for deeper read; investors can review the call for management color on reimbursement cadence and R&D timelines. Earnings Call Transcript
• Negative Sentiment: Robert W. Baird cut its price target sharply from $28 to $14 and moved to a Neutral rating — a downgrade in sell‑side enthusiasm that likely pressured the stock. The Fly: Baird PT Cut
• Negative Sentiment: Despite revenue growth, losses remain large (Q4 net loss $13.5M; FY2025 net loss $73.2M) and adjusted EBITDA is negative — capital‑intensive R&D and sales investments keep profitability distant. Zacks: Q4 Loss, Revenue Beat
• Negative Sentiment: Two law firms have public investor‑investigation notices related to Beta Bionics — these alerts can increase uncertainty and trading volatility. Newsfile: Faruqi & Faruqi Notice GlobeNewswire: Pomerantz Alert
• Negative Sentiment: Investor‑level headwinds: notable insider selling and mixed analyst targets (some high convictions remain, but divergence increases short‑term uncertainty). Quiver/Investor Data

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. Engineers Gate Manager LP bought a new stake in Beta Bionics in the fourth quarter worth $251,000. Eversept Partners LP bought a new position in Beta Bionics in the 4th quarter worth about $20,667,000. Balyasny Asset Management L.P. grew its position in Beta Bionics by 3,278.6% during the 4th quarter. Balyasny Asset Management L.P. now owns 84,973 shares of the company’s stock valued at $2,589,000 after purchasing an additional 82,458 shares during the last quarter. 12 West Capital Management LP bought a new stake in Beta Bionics during the 4th quarter valued at about $17,520,000. Finally, Freestone Grove Partners LP bought a new stake in Beta Bionics during the 4th quarter valued at about $4,209,000.

Beta Bionics Stock Down 10.7%

The firm’s fifty day simple moving average is $22.10 and its 200-day simple moving average is $22.60. The firm has a market capitalization of $549.05 million and a PE ratio of -2.85.

Beta Bionics (NASDAQ:BBNX) last announced its quarterly earnings data on Tuesday, February 17th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.12. The company had revenue of $32.12 million during the quarter. Beta Bionics had a negative net margin of 87.89% and a negative return on equity of 35.72%.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.